Ryan Specialty (NYSE:RYAN) Issues Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Ryan Specialty (NYSE:RYAN) announced its earnings results on Thursday. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.60 by $0.14, FiscalAI reports. The business had revenue of $916.65 million during the quarter, compared to analysts’ expectations of $873.93 million. Ryan Specialty had a net margin of 8.21% and a return on equity of 41.33%. The firm’s revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.66 earnings per share.

Here are the key takeaways from Ryan Specialty’s conference call:

• Second-quarter results exceeded expectations, with revenue up 7.2% to $917 million, organic growth of 6.7%, adjusted EBITDA up 6% to $327 million, and adjusted EPS up 12.1% to $0.74. First-half organic growth reached 8.9%, while management raised its full-year organic growth outlook to the higher end of the mid-single-digit range.
• Ryan Specialty repurchased 8.1 million shares for $260 million during the quarter, authorized an additional $300 million for buybacks, and repurchased another $42 million in July. Net leverage ended at 3.3 times, within management’s targeted 3-to-4-times range.
• The company expects continued pressure from declining property pricing, heightened competition in casualty and binding authority, builders-risk headwinds, and a difficult third-quarter comparison. Full-year adjusted EBITDA margin is now expected to decline approximately 50 to 100 basis points, reflecting talent investments, lower fiduciary income, and higher healthcare costs.
• Management highlighted strong performance in casualty construction, professional lines, transactional liability, and reinsurance, supported by a robust pipeline and continued specialty-market demand. Investments in AI, alternative capital solutions, benefits, and new underwriting businesses are intended to improve productivity, diversify revenue, and support longer-term growth.
• Management said it is unlikely to close a meaningful acquisition in 2026 and is instead evaluating opportunities for 2027, while maintaining a disciplined approach focused on strategic fit, cultural alignment, and accretion.

Ryan Specialty Stock Performance

Shares of Ryan Specialty stock traded down $2.42 during trading on Thursday, hitting $44.06. 2,593,910 shares of the stock were exchanged, compared to its average volume of 1,943,053. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 2.90. The company has a fifty day moving average price of $37.51 and a 200-day moving average price of $38.39. The stock has a market capitalization of $11.62 billion, a price-to-earnings ratio of 57.22, a price-to-earnings-growth ratio of 1.01 and a beta of 0.61. Ryan Specialty has a 1-year low of $29.28 and a 1-year high of $61.85.

Ryan Specialty declared that its board has authorized a stock repurchase program on Tuesday, May 26th that permits the company to buyback $300.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 3.5% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Ryan Specialty

In other Ryan Specialty news, Director John W. Rogers, Jr. purchased 7,500 shares of Ryan Specialty stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average price of $35.16 per share, for a total transaction of $263,700.00. Following the completion of the acquisition, the director owned 117,933 shares of the company’s stock, valued at approximately $4,146,524.28. This trade represents a 6.79% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mark Stephen Katz purchased 3,215 shares of the stock in a transaction on Wednesday, June 3rd. The shares were acquired at an average cost of $31.07 per share, for a total transaction of $99,890.05. Following the transaction, the executive vice president owned 4,332 shares of the company’s stock, valued at approximately $134,595.24. The trade was a 287.82% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders bought 130,715 shares of company stock worth $4,263,590. Insiders own 52.03% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Quadrant Capital Group LLC boosted its position in Ryan Specialty by 774.5% during the fourth quarter. Quadrant Capital Group LLC now owns 13,493 shares of the company’s stock worth $697,000 after purchasing an additional 11,950 shares during the period. Vanguard Personalized Indexing Management LLC raised its position in shares of Ryan Specialty by 13.8% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 12,993 shares of the company’s stock valued at $671,000 after purchasing an additional 1,576 shares during the period. Oxford Asset Management LLP bought a new position in shares of Ryan Specialty in the fourth quarter valued at about $428,000. Creative Planning lifted its stake in shares of Ryan Specialty by 15.4% during the 2nd quarter. Creative Planning now owns 4,586 shares of the company’s stock worth $312,000 after buying an additional 613 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new stake in shares of Ryan Specialty during the 4th quarter worth about $244,000. 84.82% of the stock is owned by institutional investors and hedge funds.

Ryan Specialty News Summary

Here are the key news stories impacting Ryan Specialty this week:

• Positive Sentiment: Ryan Specialty reported adjusted earnings of $0.74 per share, ahead of consensus estimates ranging from $0.60 to $0.61 and up from $0.66 a year earlier. Ryan Specialty Group Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Second-quarter revenue increased 7.2% year over year to approximately $916.6 million, exceeding the roughly $874 million analyst estimate. The results indicate continued demand for the specialty insurance broker’s services. Ryan Specialty Reports Second Quarter 2026 Results
• Positive Sentiment: The earnings beat initially prompted a sharp positive market reaction, highlighting that profitability and revenue remained stronger than analysts had anticipated. Ryan Specialty Reports Strong Q2 CY2026
• Neutral Sentiment: Organic revenue growth was 6.7%, down from 7.1% in the prior-year quarter. That remains solid growth but suggests some moderation in underlying business momentum. Ryan Specialty Q2 Earnings Key Metrics
• Negative Sentiment: Net income declined 13.1% year over year, creating a notable contrast with the revenue and adjusted-EPS growth. Investors may be concerned that higher earnings were not accompanied by stronger bottom-line results. Ryan Specialty Second Quarter Results
• Negative Sentiment: The reaction also reflects elevated expectations and valuation sensitivity: a strong earnings beat may not be enough to sustain the stock if investors focus on slower organic growth and declining net income.

Wall Street Analysts Forecast Growth

RYAN has been the subject of a number of recent research reports. Wolfe Research downgraded shares of Ryan Specialty from an “outperform” rating to a “peer perform” rating in a research note on Thursday, July 9th. The Goldman Sachs Group lifted their target price on Ryan Specialty from $35.00 to $40.00 and gave the company a “neutral” rating in a research report on Wednesday, July 1st. Piper Sandler upped their target price on Ryan Specialty from $40.00 to $44.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Atlantic Securities set a $69.00 price target on Ryan Specialty in a research report on Wednesday, July 15th. Finally, Barclays raised their price target on Ryan Specialty from $39.00 to $46.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $50.00.

Ryan Specialty Company Profile

Ryan Specialty Group, Inc (NYSE: RYAN) is a global specialty insurance and reinsurance platform that partners with a network of insurers and reinsurers to deliver tailored risk solutions. The company focuses on complex and large-scale risks across multiple industry sectors, leveraging its underwriting expertise to structure coverage programs that meet clients’ unique needs.

Ryan Specialty’s core offerings span a diverse range of specialty lines, including casualty, property, professional liability, marine and energy, program administration, and sports and entertainment.